Polaris Pharmaceuticals, Inc

4941 Allison Parkway, Suite B
United States

Tel: 707-451-0441

Email: support@polarispharma.com

Featured Employer
Show jobs for this employer

About Polaris Pharmaceuticals, Inc

Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP Production Facilities in Northern California and China

Stock Exchange: Taiwan

Stock Symbol: 6550.TDW

6 articles with Polaris Pharmaceuticals, Inc